VERU INC. - COMMON STOCK

0,5811

06-февраля-25 16:45:00

15 мин. задержка

Акции

+0,0028

+0,48%

Сегодняшний диапазон

0,5600 - 0,6189

ISIN

N/A

Источник

NASDAQ

Veru Reports Fiscal 2024 Second Quarter Financial Results and Progress of its Enobosarm High Quality Weight Loss Clinical Program

08 май 2024 06:30:00 Источник Nasdaq GlobeNewswire
Veru to Present at the GLP-1 Based Therapeutics Summit

02 май 2024 08:30:00 Источник Nasdaq GlobeNewswire
Veru to Report Fiscal 2024 Second Quarter Financial Results on May 8, 2024

01 май 2024 08:30:37 Источник Nasdaq GlobeNewswire
Veru Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

30 апр 2024 08:30:00 Источник Nasdaq GlobeNewswire
Veru to Present at the American Association of Clinical Endocrinology (AACE) 2024 Annual Meeting on May 9-11

25 апр 2024 08:30:00 Источник Nasdaq GlobeNewswire
Veru Announces Date of 2024 Annual Meeting of Shareholders

01 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire
Veru Reschedules Annual Meeting of Shareholders

22 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire
Veru Announces the Appointment of Louis Aronne MD as Chief Medical Advisor for its Enobosarm Program for High Quality Weight Loss

12 мар 2024 08:00:00 Источник Nasdaq GlobeNewswire
Veru Announces Notification from Nasdaq Related to Delayed Quarterly Report on Form 10-Q

27 фев 2024 19:15:00 Источник Nasdaq GlobeNewswire
Veru Announces New Scientific Advisory Board for its Enobosarm Program for High Quality Weight Loss

20 фев 2024 08:30:00 Источник Nasdaq GlobeNewswire
Veru Reports Fiscal 2024 First Quarter Financial Highlights

08 фев 2024 06:30:00 Источник Nasdaq GlobeNewswire
Veru Announces FDA Clearance of IND Application to Initiate Phase 2b Clinical Trial with Enobosarm to Treat Muscle Loss Associated with Weight Loss Drugs

06 фев 2024 08:30:00 Источник Nasdaq GlobeNewswire
Veru to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

31 янв 2024 08:30:00 Источник Nasdaq GlobeNewswire
Veru to Report Fiscal 2024 First Quarter Financial Results on February 8, 2024

25 янв 2024 08:30:00 Источник Nasdaq GlobeNewswire
Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

08 янв 2024 08:30:00 Источник Nasdaq GlobeNewswire
Veru to Host Investor Call on January 4th, 2024 to Discuss Recent Financing and Strategy to Prioritize the Development of Enobosarm as a Combination Treatment to Prevent Muscle Loss and Augment Fat Loss Associated with Weight Loss GLP-1 Drugs

19 дек 2023 08:30:00 Источник Nasdaq GlobeNewswire
Veru Announces Pricing of Public Offering of Common Stock

14 дек 2023 09:00:00 Источник Nasdaq GlobeNewswire
Veru Announces Proposed Public Offering of Common Stock

13 дек 2023 16:01:28 Источник Nasdaq GlobeNewswire
Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study

04 окт 2023 08:30:00 Источник Nasdaq GlobeNewswire
Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)

26 сен 2023 08:30:00 Источник Nasdaq GlobeNewswire

<<
<
1
2
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.